PDE10A and Huntington disease: Alterations in expressions of adenosine A1 and A2, cannabinoid CB1, dopaminergic D1 and D2 and glutamatergic mGluR5 receptors, together with activation of microglia, PDE10A and SV2A protein dysfunction have been considered as promising biomarkers of HD.